Key Takeaways Pfizer's non-COVID revenues grew on strong in-line, new and acquired products.New and acquired products delivered $4.7B in first-half 2025 sales, up about 15$10B in 2030 risk-adjusted revenues with significant growth potential.With the end of the pandemic, sales of Pfizer’s (PFE) COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its key ...